Today: 29 June 2026
Browse Category

LSE:GSK 31 January 2026 - 9 June 2026

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent surged Tuesday after GSK said it would buy the Nasdaq-listed biotech for $10.6 billion, or $124 a share in cash. The stock shot up 38.9% to $122.93, almost reaching the offer price and trading like the day’s standard merger-arb play. That wasn’t a full biotech sector rally. The SPDR S&P Biotech ETF climbed 2.1%, while the iShares Nasdaq Biotechnology ETF put on 1.4%. Nuvalent’s pop looked like a move on its own news, not a general sector rebound.
9 June 2026
···
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK is set to acquire U.S.-based Nuvalent for $10.6 billion in cash, making it the largest deal GSK has made in years. The offer is $124 per share, which works out to a 40% premium on Nuvalent’s previous closing price. It’s an early move by CEO Luke Miels as he looks to revamp the British group’s oncology pipeline. GSK is looking for late-stage drugs as it braces for patent expiry on dolutegravir, its main HIV therapy, between 2028 and 2030. After that, cheaper products could hit sales. Nuvalent could bring in new revenue as early as 2027 and give GSK a shot at keeping annual sales above 40 billion pounds by 2031.
9 June 2026
··
FTSE 100 Falls Today as AstraZeneca and GSK Drag London Stocks Lower

FTSE 100 Falls Today as AstraZeneca and GSK Drag London Stocks Lower

London’s FTSE 100 slipped 0.6% to 10,270.96 as of 10:39 BST, while the FTSE 250 hovered, edging down just 0.05% to 22,389.12. This shift caught attention, landing just a day after the blue-chip index finally snapped a six-day slide. Energy stocks gave that rebound a lift, but it fizzled fast on Wednesday. Traders were staring down a packed earnings calendar, climbing oil prices, and looming central-bank calls in the U.S., euro zone, and UK.
29 April 2026
···
GSK steps up share buyback as fresh annual report spells out CEO Luke Miels’ 2026 priorities

GSK steps up share buyback as fresh annual report spells out CEO Luke Miels’ 2026 priorities

GSK picked up 650,000 shares on Thursday for its buyback, paying prices from 2,072 pence up to 2,135 pence apiece. Those shares are headed for treasury, according to the company. GSK’s acquisition comes as the company works to advance its pipeline and stick to its shareholder-returns roadmap under new CEO Luke Miels, who stepped in at the end of December, following Emma Walmsley’s departure.
6 March 2026
··
GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

London, February 19, 2026, 09:14 GMT — Regular session GSK slipped 0.39% to 2,259 pence by 0901 GMT in early London trading, following new real-world data on its RSV shot Arexvy and the stock going ex-dividend. The shares had kicked off at 2,252 pence, just a day after touching a 52-week peak of 2,282 pence; they’ve climbed roughly 57% in the last year.
19 February 2026
····
GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

GSK is projecting slower sales growth in 2026 under new CEO Luke Miels, who took over from Emma Walmsley earlier this year. The company is bracing for patent expiries on its leading HIV drugs starting in 2028. It now expects revenue growth of 3% to 5% at constant currency, while warning that vaccines and general medicines sales might decline. Shares climbed 1.4% by 0809 GMT after an initial drop. Core earnings per share for Q4 came in at 25.5 pence, supported by an 8% sales increase to £8.62 billion. This marks the first time Miels has laid down concrete targets. The company needs to sustain its cash flow while ramping up new product launches and advancing late-stage trials.
4 February 2026
·
1 2 3 4

Stock Market Today

  • Cybersecurity ETF (BUG) jumps; Emerging Markets ETF (EMEQ) lags on Monday
    June 29, 2026, 1:07 PM EDT. The Global X Cybersecurity ETF (BUG) climbed 3.9% Monday, lifted by strong gains from Gorilla Technology Group and Palo Alto Networks, up 8.4% and 7.8%. The Nomura Focused Emerging Markets Equity ETF (EMEQ) fell about 3.6%. DR. Reddys Laboratories slipped 3.1% and Turkcell Iletisim Hizmetleri lost 2.6% in EMEQ. Cybersecurity saw sector gains, while emerging markets stocks sold off in the session.
Go toTop